Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali

Alassane Dicko, Issaka Sagara, Mahamadou S Sissoko, Ousmane Guindo, Abdoulbaki I Diallo, Mamady Kone, Ousmane B Toure, Massambou Sacko, Ogobara K Doumbo, Alassane Dicko, Issaka Sagara, Mahamadou S Sissoko, Ousmane Guindo, Abdoulbaki I Diallo, Mamady Kone, Ousmane B Toure, Massambou Sacko, Ogobara K Doumbo

Abstract

Background: Recent studies have shown that intermittent preventive malaria treatment (IPT) in infants in areas of stable malaria transmission reduces malaria and severe anaemia incidence. However in most areas malaria morbidity and mortality remain high in older children.

Methods: To evaluate the effect of seasonal IPT with sulphadoxine pyrimethamine (SP) on incidence of malaria disease in area of seasonal transmission, 262 children 6 months-10 years in Kambila, Mali were randomized to receive either IPT with SP twice at eight weeks interval or no IPT during the transmission season of 2002 and were followed up for 12 months. Subjects were also followed during the subsequent transmission season in 2003 to assess possible rebound effect. Clinical malaria cases were treated with SP and followed to assess the in vivo response during both periods.

Results: The incidence rate of malaria disease per 1,000 person-months during the first 12 months was 3.2 episodes in the treatment group vs. 5.8 episodes in the control group with age-adjusted Protective Efficacy (PE) of 42.5%; [95% CI 28.6%-53.8%]. When the first 16 weeks of follow up is considered age-adjusted PE was 67.5% [95% CI 55.3% - 76.6%]. During the subsequent transmission season, the incidence of clinical malaria per 1000 persons-days was similar between the two groups (23.0 vs 21.5 episodes, age-adjusted IRR = 1.07 [95% CI, 0.90-1.27]). No significant difference was detected in in vivo response between the groups during both periods.

Conclusion: Two malaria intermittent treatments targeting the peak transmission season reduced the annual incidence rate of clinical malaria by 42.5% in an area with intense seasonal transmission. This simple strategy is likely to be one of the most effectives in reducing malaria burden in such areas.

Trial registration: Clinicaltrials.gov NCT00623155.

Figures

Figure 1
Figure 1
Flow Chart.

References

    1. World Health Organization . World Health Report 2002: Reducing risks, Promoting Healthy life. Geneva: WHO; 2002. Burden of disease in DALYs by cause sex and mortality stratum in the WHO regions, estimates for 2001; pp. 192–197.
    1. Adjuik M, Smith T, Clark S, Todd J, Garrib A, Kinfu Y, Kahn K, Mola M, Ashraf A, Masanja H, Adazu K, Sacarlal J, Alam N, Marra A, Gbangou A, Mwageni E, Binka F. Cause-specific mortality rates in sub-Saharan Africa and Bangladesh. Bull World Health Organ. 2006;84:181–188. doi: 10.2471/BLT.05.026492.
    1. Duflo B, Balique H, Ranque P, Diallo AN, Brucker G, Alavi H, Prescott N. [Estimation of the impact of the principal diseases in rural Mali] Rev Epidemiol Sante Publique. 1986;34:405–418.
    1. Théra MA, D'Alessandro U, Thiéro M, Ouedraogo A, Packou J, Deida OAS, Fané M, Ade G, Alvez F, Doumbo O. Child malaria treatment practices among mothers in the district of Yanfolila, Sikasso Region, Mali. Trop Med Int Health. 2000;5:876–881. doi: 10.1046/j.1365-3156.2000.00652.x.
    1. Health Systems and Operational Research Focus Group Report International Conference on malaria in Africa: Challenges and opportunities for cooperation Final Report, Dakar. 1997.
    1. Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg. 2001;64:12–17.
    1. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, Mshinda H, Alonso P. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet. 2001;357:1471–1477. doi: 10.1016/S0140-6736(00)04643-2.
    1. Massaga JJ, Kitua AY, Lemnge MM, Akida JA, Malle LN, Ronn AM, Theander TG, Bygbjerg IC. Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial. Lancet. 2003;361:1853–1860. doi: 10.1016/S0140-6736(03)13504-0.
    1. Greenwood BM. The use of anti-malaria drugs to prevent malaria in the population of malaria-endemic areas. Am J Trop Med Hyg. 2004;70:1–7.
    1. Diourté Y, Djimde A, Doumbo O, Sagara I, Coulibaly Y, Dicko A, Diallo M, Diakite M, Cortese JF, Plowe CV. Pyrimethamine sulfadoxine efficacity and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. Am J Trop Med Hyg. 1999;60:475–478.
    1. World Health Organization Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria WHO/HTM/RBM/200350.
    1. Cisse B, Sokhna C, Boulanger D, Milet J, Ba el H, Richardson K, Hallett R, Sutherland C, Simondon K, Simondon F, Alexander N, Gaye O, Targett , Lines J, Greenwood B, Trape JF. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet. 2006;367:659–667. doi: 10.1016/S0140-6736(06)68264-0.
    1. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, Mensah N, Jaffar S, Baiden R, Hodgson A, Binka F, Greenwood B. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ. 2005;331:727–733. doi: 10.1136/bmj.331.7519.727.
    1. Macete E, Aide P, Aponte JJ, Sanz S, Mandomando I, Espasa M, Sigauque B, Dobano C, Mabunda S, Dgedge M, Alonso P, Menendez C. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in mozambican infants: a randomized, placebo-controlled trial. J Infect Dis. 2006;194:276–285. doi: 10.1086/505431.
    1. Trape JF, Rogier C. Combating malaria morbidity and mortality by reducing transmission. Parasitol Today. 1996;12:236–240. doi: 10.1016/0169-4758(96)10015-6.
    1. Coulibaly D, Diallo DA, Thera MA, Dicko A, Guindo AB, Kone AK, Cissoko Y, Coulibaly S, Djimde A, Lyke K, Doumbo O, Plowe CV. Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am J Trop Med Hyg. 2002;67:604–610.
    1. Lalloo DG, Olukoya P, Olliaro P. Malaria in adolescence: burden of disease, consequences, and opportunities for intervention. Lancet Infect Dis. 2006;6:780–793. doi: 10.1016/S1473-3099(06)70655-7.
    1. Dicko A, Sagara I, Diemert DJ, Sogoba M, Niambélé MB, Dao A, Dolo G, Yalcouyé D, Diallo DA, Saul A, Miller LH, Touré YT, Klion A, Doumbo OK. Year-to-year variation in the age-specific incidence of malaria in two potential vaccine testing sites in Mali with different levels of malaria transmission intensity. Am J Trop Med Hyg. 2007;77:1028–1033.
    1. Greenwood B. Intermittent preventive antimalarial treatment in infants. Clin Infect Dis. 2007;45:26–28. doi: 10.1086/518574.
    1. Chandramohan D, Webster J, Smith L, Awine T, Owusu-Agyei S, Carneiro I. Is the Expanded Programme on Immunisation the most appropriate delivery system for intermittent preventive treatment of malaria in West Africa. Trop Med Int Health. 2007;12:743–750.
    1. Sissoko MS, Dicko A, Briet OJ, Sissoko M, Sagara I, Keita HD, Sogoba M, Rogier C, Toure YT, Doumbo OK. Malaria incidence in relation to rice cultivation in the irrigated Sahel of Mali. Acta Trop. 2004;89:161–170. doi: 10.1016/j.actatropica.2003.10.015.
    1. Rhee M, Sissoko M, Perry S, Dicko A, McFarland W, Doumbo O. Malaria prevention practices in Mopti region, Mali. East Afr Med J. 2005;82:396–402.
    1. Miller JM, Korenromp EL, Nahlen BLW, Steketee R. Estimating the number of insecticide-treated nets required by African households to reach continent-wide malaria coverage targets. JAMA. 2007;297:2241–2250. doi: 10.1001/jama.297.20.2241.
    1. Hill J, Lines J, Rowland M. Insecticide-treated nets. Adv Parasitol. 2006;61:77–128. doi: 10.1016/S0065-308X(05)61003-2.
    1. Lyke KE, Dicko A, Kone A, Coulibaly D, Guindo A, Cissoko Y, Traore K, Plowe CV, Doumbo OK. Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali. Vaccine. 2004;22:3169–3174. doi: 10.1016/j.vaccine.2004.01.054.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner